Talk:COVID-19 drug development#Promising new Israeli therapeutic

{{WikiProject banner shell|class=B|1=

{{WikiProject COVID-19|importance=High|needs-infobox=no|needs-image=Yes}}

{{WikiProject Medicine|importance=Mid|pulmonology=yes|pulmonology-imp=mid|image-needed=yes}}

{{WikiProject International relations |importance=Mid |needs-infobox=no}}

}}

{{split to|from=COVID-19 drug development|to=Bamlanivimab|date=10 December 2020}}

{{User:MiszaBot/config

| algo=old(14d)

| archive=Talk:COVID-19 drug development/Archive %(counter)d

| counter=1

| maxarchivesize=150K

| archiveheader={{Automatic archive navigator}}

| minthreadsleft=3

| minthreadstoarchive=1

}}

Include interferon lambda in the list of drugs being tested for COVID.

Multiple clinical trials are investigating the use of Interferon Lambda to treat COVID.https://clinicaltrials.gov/ct2/show/NCT04354259https://clinicaltrials.gov/ct2/show/NCT04354259https://clinicaltrials.gov/ct2/show/NCT04331899

Add sabizabulin

Sabizabulin "halved the death rate among critically ill Covid patients who were receiving supplemental oxygen and were at high risk for serious lung disease and death"

New Drug Slashed Deaths Among Patients With Severe Covid, Maker Claims https://www.nytimes.com/2022/04/11/health/covid-sabizabulin-veru.html

National Center for Biotechnology Information (2022). PubChem Compound Summary for CID 53379371, Sabizabulin. Retrieved April 12, 2022 from https://pubchem.ncbi.nlm.nih.gov/compound/Sabizabulin

Sabizabulin (VERU-111) for

COVID-19 https://verupharma.com/pipeline/sabizabulin-for-covid-19/

Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy https://www.globenewswire.com/news-release/2022/04/11/2419839/11676/en/Veru-s-Novel-COVID-19-Drug-Candidate-Reduces-Deaths-by-55-in-Hospitalized-Patients-in-Interim-Analysis-of-Phase-3-Study-Independent-Data-Monitoring-Committee-Halts-Study-Early-for-.html

2600:1000:B00F:64AC:D8E9:99AA:2866:936 (talk) 13:50, 12 April 2022 (UTC)

:Thanks for posting this. We would not use the press releases as reliable sources for this information, so need to wait for peer reviewed articles or independent newspaper reports before including the supposed efficacy. In addition, this might be more suitable for this article - COVID-19 drug repurposing research - as the drug was in development already for cancer. Either way, I expect there will be more information published soon and if the press report is borne out then it should be included.

:Currently, [https://link.springer.com/article/10.1007/s40267-022-00897-8/tables/5 one review] lists the trial in a table , and it has [https://clinicaltrials.gov/ct2/show/NCT04842747 a listing] on ClinicalTrials.gov. |→ Spaully ^~talk~ 14:14, 12 April 2022 (UTC)

Semi-protected edit request on 28 July 2023

Specia = Special 2603:8000:D300:D0F:2098:B4E2:5069:2E94 (talk) 04:55, 28 July 2023 (UTC)

:File:Red information icon with gradient background.svg Not done: That appears to be a person's last name, located in a reference to [https://web.archive.org/web/20211128050911/https://www.nytimes.com/2021/11/04/business/britain-covid-merck-antiviral.html this article] which lists Megan Specia as an author. Tollens (talk) 05:13, 28 July 2023 (UTC)